A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
This study has been completed.
First Posted: November 30, 2011
Last Update Posted: April 24, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 31, 2014|
|Primary Completion Date:||January 31, 2014 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||August 9, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016.